Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter L M Jansen

Showing results (11-20 of 107) with videos related to

Pageof 11
Sort By:
Nederlands Tijdschrift Voor Geneeskunde|December 12, 2013
[Bariatric surgery: part of a systematic approach to obesity]Peter L M Jansen
Lancet (London, England)|October 11, 2003
Paediatric cholestasis: is villin the villain?Peter L M Jansen, Ekkehard Sturm
Liver International : Official Journal of the International Association for the Study of the Liver|January 8, 2004
Genetic cholestasis, causes and consequences for hepatobiliary transportPeter L M Jansen, Ekkehard Sturm
Expert Opinion on Investigational Drugs|December 1, 2011
Controlled-release interferon alpha 2b, a new member of the interferon family for the treatment of chronic hepatitis CPeter L M Jansen, Joep De Bruijne
Journal of Hepatology|June 27, 2006
Antiviral effect of peginterferon alfa-2b and alfa-2a comparedPeter L M Jansen, Henk W Reesink
Hepatology (Baltimore, Md.)|October 15, 2013
How sweet it is to activate FXRPeter L M Jansen, Frank G Schaap
Hepatology (Baltimore, Md.)|November 25, 2015
Pandora's box opens for cholestatic liver diseasePeter L M Jansen, Frank G Schaap
Journal of Hepatology|February 14, 2015
Pituitary TSH controls bile salt synthesisPeter L M Jansen, Frank G Schaap
Journal of Hepatology|February 9, 2012
Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinomaFlorie Borel, Pavlina Konstantinova, Peter L M Jansen
Advanced Drug Delivery Reviews|January 22, 2003
Drug transport proteins in the liverKlaas Nico Faber, Michael Müller, Peter L M Jansen
Pageof 11

Showing results (11-20 of 107) with videos related to

Sort By:
Pageof 11
Nederlands Tijdschrift Voor Geneeskunde|December 12, 2013
[Bariatric surgery: part of a systematic approach to obesity]Peter L M Jansen
Lancet (London, England)|October 11, 2003
Paediatric cholestasis: is villin the villain?Peter L M Jansen, Ekkehard Sturm
Liver International : Official Journal of the International Association for the Study of the Liver|January 8, 2004
Genetic cholestasis, causes and consequences for hepatobiliary transportPeter L M Jansen, Ekkehard Sturm
Expert Opinion on Investigational Drugs|December 1, 2011
Controlled-release interferon alpha 2b, a new member of the interferon family for the treatment of chronic hepatitis CPeter L M Jansen, Joep De Bruijne
Journal of Hepatology|June 27, 2006
Antiviral effect of peginterferon alfa-2b and alfa-2a comparedPeter L M Jansen, Henk W Reesink
Hepatology (Baltimore, Md.)|October 15, 2013
How sweet it is to activate FXRPeter L M Jansen, Frank G Schaap
Hepatology (Baltimore, Md.)|November 25, 2015
Pandora's box opens for cholestatic liver diseasePeter L M Jansen, Frank G Schaap
Journal of Hepatology|February 14, 2015
Pituitary TSH controls bile salt synthesisPeter L M Jansen, Frank G Schaap
Journal of Hepatology|February 9, 2012
Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinomaFlorie Borel, Pavlina Konstantinova, Peter L M Jansen
Advanced Drug Delivery Reviews|January 22, 2003
Drug transport proteins in the liverKlaas Nico Faber, Michael Müller, Peter L M Jansen
Pageof 11